Clemence Santana

Valence, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium.

Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium.

Journal: British journal of haematology

Published: March 05, 2026

Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes.

Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes.

Journal: Leukemia

Published: November 06, 2025

Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry.

Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry.

Journal: Leukemia

Published: October 25, 2025

Individualized physical activity program for older adults undergoing chemotherapy for hematologic malignancies.

Individualized physical activity program for older adults undergoing chemotherapy for hematologic malignancies.

Journal: Journal of geriatric oncology

Published: October 10, 2025

Allogeneic hematopoietic stem cell transplantation after azacitidine and venetoclax salvage in relapsed/refractory AML: a multicenter real-world study by the French AURAML group.

Allogeneic hematopoietic stem cell transplantation after azacitidine and venetoclax salvage in relapsed/refractory AML: a multicenter real-world study by the French AURAML group.

Journal: Bone marrow transplantation

Published: October 01, 2025

Efficacy and safety of luspatercept with or without erythropoiesis-stimulating agent in patients with myelodysplastic neoplasms with ring sideroblasts: A multicentre real-life study by the GFM.

Efficacy and safety of luspatercept with or without erythropoiesis-stimulating agent in patients with myelodysplastic neoplasms with ring sideroblasts: A multicentre real-life study by the GFM.

Journal: British journal of haematology

Published: March 28, 2025

Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY Study.

Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY Study.

Journal: Clinical hematology international

Published: March 18, 2025

Clinical outcome of therapy-related acute myeloid leukemia patients. Real-life experience in a University Hospital and a Cancer Center in France.

Clinical outcome of therapy-related acute myeloid leukemia patients. Real-life experience in a University Hospital and a Cancer Center in France.

Journal: Cancer medicine

Published: January 13, 2023

Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM).

Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM).

Journal: Transfusion

Published: September 08, 2021

Individualised physical activity programme in patients over 65 years with haematological malignancies (OCAPI): protocol for a single-arm feasibility trial.

Individualised physical activity programme in patients over 65 years with haematological malignancies (OCAPI): protocol for a single-arm feasibility trial.

Journal: BMJ open

Published: June 04, 2021

Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.

Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.

Journal: British journal of haematology

Published: February 02, 2021

Showing 1-11 of 11

Last Updated: 09/26/2026